Anti-PBD Antibody Screening Panel

Catalog # APA-04

Product Details

This antibody panel comprises two distinct rabbit monoclonal antibodies against Pyrrolobenzodiazepine (PBD), with slight differences in their recognition epitopes. Consequently, they may exhibit varying affinity levels towards different PBD analogs or different conjugates of PBD and linkers. This panel can be used to conduct preliminary experiments for screening the optimal antibody clone.

Components

Cat.No.	Clone	Size
PAD-MY2221	M1D08	20 ug
PAD-MY2212	1M1F9	20 ug

Specificity

Specifically recognizes PBD.

Source

This panel contains Two anti-PBD monoclonal antibodies, suitable for pharmacokinetic (PK) detection of ADC with PBD as the payload. All the anti-PBD monoclonal antibodies are recombinantly expressed from HEK293, can be used as a capture antibody for detecting conjugated antibodies in ELISA assay.

Isotype

Rabbit IgG | Rabbit Kappa

Purification

Protein A purified / Protein G purified

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

ACRO Quality Management System

- QMS(ISO, GMP)
- Quality Advantages
- Quality Control Process

Bioactivity-ELISA



Immobilized Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (M1D08) (Cat. No. PAD-MY2221) at 1 μg/mL, add Loncastuximab Tesirine in the 100% Human Serum and then add Biotinylated Human CD19 (20-291), His,Avitag, premium grade (Cat. No. CD9-H82E9) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).



Immobilized Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) (Cat. No. PAD-MY2212) at 1 μg/mL, add Loncastuximab Tesirine in the 100% Human Serum and then add Biotinylated Human CD19 (20-291), His,Avitag, premium grade (Cat. No. CD9-H82E9) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).

Background

Pyrrolobenzodiazepine (PBD) dimer, is a new generation of cytotoxic payload used in antibody-drug conjugates (ADCs). The PBD dimer binds to the minor groove of DNA to form effective cytotoxic DNA interstrand crosslinks, which can block cell division and kill cancer cells. This mechanism of action utilizes a completely different cellular target from that of tubulin inhibitors, as well as a different DNA damage pattern from other DNA-targeting payloads. Anti-PBD antibody is a rabbit monoclonal antibody specially reacts with PBD, which is more sensitive than mouse antibody. The anti-PBD antibody is a useful reagent in PK assay to determine conjugated antibodies.